61results about How to "Improve hemodynamics" patented technology

Surgical systems for less invasive access to and isolation of an atrial appendage are provided. A suturing grasper compresses soft tissue structures and deploys one or more sutures through complimentary pledget(s) carried by the grasper. The pledgets are reinforced, containing support members that define the profile of the stitch and distribute stresses applied by the stitch, once tightened, over a length of tissue. This hardware may be applicable to other surgical and catheter based applications as well including: compressing soft tissue structures lung resections and volume reductions; gastric procedures associated with reduction in volume, aneurysm repair, vessel ligation, or other procedure involving isolation of, resection of, and reduction of anatomic structures.

Surgical systems for less invasive access to and isolation of an atrial appendage are provided. A suturing grasper compresses soft tissue structures and deploys one or more sutures through complimentary pledget(s) carried by the grasper. The pledgets are reinforced, containing support members that define the profile of the stitch and distribute stresses applied by the stitch, once tightened, over a length of tissue. This hardware may be applicable to other surgical and catheter based applications as well including: compressing soft tissue structures lung resections and volume reductions; gastric procedures associated with reduction in volume, aneurysm repair, vessel ligation, or other procedure involving isolation of, resection of, and reduction of anatomic structures.

An endoluminal prosthesis comprises a prosthetic trunk comprising a trunk lumen extending therethrough, a wall, and an anastomosis in the wall, wherein the prosthetic trunk has a circumference. The endoluminal prosthesis further comprises a prosthetic branch comprising a branch lumen extending therethrough. The branch lumen is in fluid communication with the trunk lumen through the anastomosis. The prosthetic branch is disposed longitudinally along and circumferentially about the prosthetic trunk.

An apparatus and method for treating ventricular tachycardia in which paces are delivered to the ventricles at multiple pacing sites in accordance with an anti-tachycardia pacing protocol. Paces are delivered at a selected offset interval in a manner that both resynchronizes ventricular contractions and increases the probability of terminating the tachycardia.

Materials, devices and methods for the treatment of congestive heart failure are disclosed. In these methods, the volume of the left ventricle is reduced, thereby increasing the efficiency of the pumping action of the heart. Volume reduction is accomplished by introduction of biocompatible materials into the wall of the left ventricle, or into the ventricle itself. Also disclosed is a method for ventricular geometry reduction wherein flexible, elastic bands are attached to the external surface of the heart to affect a decrease in the volume of the left ventricle. Other disclosed devices include catheters and elastic bands that are usable in these treatments. Finally, disclosed is a device having an anchor disposed proximate the heart's apex, a plurality of petals, and a tensioning band secured to at least one of the petals.

Panaxadiol saponin is prepared into food product or medicine preparation capable of repairing damaged or fatigued cerebral cell and cerebral nerve cell, treating and improving insomnia and amnesia caused by long term intense nerve, improving haemodynamic and blood quality, improving brain function, and improving sleep quality.

Techniques are provided for use with implantable medical devices such as pacemakers for optimizing atrioventricular (AV) pacing delays for use with cardiac resynchronization therapy (CRT). In one example, the end of atrial mechanical contraction and the onset of isovolumic ventricular mechanical contraction are detected within a patient in which the device is implanted based on cardiomechanical signals, such as cardiogenic impedance (Z) signals, S1 heart sounds or left atrial pressure (LAP) signals. Then, a cardiomechanical time delay (MC_AV) between the end of atrial contraction and the onset of isovolumic ventricular contraction is determined. AV pacing delays are set based on MC_AV to align the end an atrial kick with the onset of isovolumic ventricular contraction. Thereafter, pacing is controlled based on the AV pacing delays.

A device includes a handle, an expandable structure including a plurality of splines extending from a proximal hub to a distal hub, a first electrode on a first spline of the plurality of splines, an outer tube extending from the handle to the proximal hub, and a shaft extending through the outer tube from the handle to the distal hub. The expandable structure has a collapsed state and a self-expanded state. The handle is configured to retract the shaft. Retracting the shaft may expand the expandable structure outward of the self-expanded state.

The present invention provides for methods and compositions for treating and / or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.

Materials, devices and methods for the treatment of congestive heart failure are disclosed. In these methods, the volume of the left ventricle is reduced, thereby increasing the efficiency of the pumping action of the heart. Volume reduction is accomplished by introduction of biocompatible materials into the wall of the left ventricle, or into the ventricle itself. Suitable biocompatible materials include those that undergo a phase transition within the ventricle or within the wall of the ventricle, and are thereby converted from a substantially liquid state to a substantially solid state. Such materials also include those which increase in volume during the transition from the liquid state to the solid state. Also disclosed is a method for ventricular geometry reduction wherein flexible, elastic bands are attached to the external surface of the heart to effect a decrease in the volume of the left ventricle. Finally, disclosed are devices including catheters and elastic bands that are usable in these treatments.

A method of facilitating therapeutic neuromodulation of a heart of a patient includes positioning an electrode in a pulmonary artery, positioning a sensor in vasculature, delivering via a stimulation system first and second electrical signals of a series of electrical signals to the electrode. The second electrical signal differs from the first electrical signal by a magnitude of a first parameter of a plurality of parameters. The method includes determining via the sensor, sensor data indicative of one or more heart activity properties in response to the delivery of the series of electrical signals, and delivering a therapeutic neuromodulation signal to the pulmonary artery using selected electrical parameters. The selected electrical parameters include a selected magnitude of the first parameter. The selected magnitude of the first parameter is based at least partially on the sensor data. The therapeutic neuromodulation signal increases heart contractility.

A method of facilitating therapeutic neuromodulation of a heart of a patient includes positioning an electrode in a pulmonary artery, positioning a sensor in vasculature, delivering via a stimulation system first and second electrical signals of a series of electrical signals to the electrode. The second electrical signal differs from the first electrical signal by a magnitude of a first parameter of a plurality of parameters. The method includes determining, via the sensor, sensor data indicative of one or more heart activity properties in response to the delivery of the series of electrical signals, and delivering a therapeutic neuromodulation signal to the pulmonary artery using selected electrical parameters. The selected electrical parameters include a selected magnitude of the first parameter. The selected magnitude of the first parameter is based at least partially on the sensor data. The therapeutic neuromodulation signal increases heart contractility.

A method of detecting catheter movement includes positioning a first sensor in a first body cavity, monitoring a first parameter profile of the first body cavity, positioning a second sensor in a second body cavity, monitoring a second parameter profile of the second body cavity, the second parameter profile different than the first parameter profile at a first time, and, when the second parameter profile is the same as the first parameter profile at a second time after the first time, taking a catheter movement action.

The invention provides a Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases and resisting fatigue, which comprises the following components in part by weight: 30 to 90 parts of glossy ganoderma extract, 40 to 120 percent of notoginseng root extract, 40 to 120 parts of root of red-rooted salvia extract and 40 to 120 parts of ginkgo leaf extract. The Chinese medicinal composition has the effects of regulating blood fat, improving hemorheology and resisting atherosclerosis, anoxia and fatigue, can reduce the level of lactic acid and serum urea and can relieve the discomfort feeling of limb weakness, oscitancy, muscular soreness, anorexia and the like which are caused by sports effectively. The invention also provides a Chinese medicinal preparation containing the Chinese medicinal composition and a preparation method thereof.

An electrotherapy apparatus comprising a sensor for detecting periodically recurring signal peaks, in particular the R-R peaks of an electrocardiogram of a person, a processor for deriving from the time interval between said periodically recurring signal peaks a time delay corresponding to approximately the end of the T-wave, and a trigger system initiated by an output signal of said processor or embodied within said processor for applying electrical stimulations to one or more active electrodes provided on the said person at a time related to the end of said time delay. The processor is adapted to generate, in addition to an initial electrical stimulation to induce muscle contraction, a plurality of further electrical stimulation pulses with intervals between each of said further electrical stimulation pulses, so that said further electrical stimulation pulses maintain said muscle contraction over a period extending from said initial electrical stimulation substantially up to a time just before a next expected R-peak.

The invention belongs to the field of a Chinese traditional medicine, in particular to a Chinese traditional compound preparation used for curing hypertension, and a method for preparing the Chinese traditional compound preparation. The compound preparation is prepared from Chinese traditional medicaments, such as radix salviae miltiorrhizae, fructus tribuli, flatstem milkvetch seed, alisma orientale and feather cockscomb seed by adopting the extraction process of optimal granules through orthogonal design experiments. The preparation is capable of promoting blood circulation by removing blood stasis and restraining the hyperactivity of the liver yang with reasonable ingredients. Proven through animal experiments and clinical research, the preparation can significantly improve such clinical symptoms as dizziness, headache, vexation vexation, insomnia, numb limbs, soreness and weakness of waist and knees, dark purple texture of tongue and petechia of body of tongue and so on; can effectively prevent the target organs from being injured resulting from hypertension, and can improve the reconstruction of hypertensive blood vessels to some extent, and can further improve the curative effect of Chinese traditional medicaments on hypertension and complications thereof.

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

A prosthetic heart valve either of the mechanical type or the bio prosthetic type, comprises a tubular or cylindrical frame element, a plurality of injectors, a suturing member surrounding the tubular or cylindrical frame element, tether lines to secure the device during diastolic filling but more predominantly during systolic contraction that creates a vortex effect with externally supplied pressurized fluid injected angularly within a transport structure is provided. Such a unit is utilized to accelerate the hemodynamics, reduce the energy required for said transport or both. The annular frame is designed to allow a passageway for blood flow and regulating flow during systolic contraction. Such a result is achieved through the introduction of pressurized fluid (blood) via a plurality of injectors situated evenly around the circumference of the subject tubular or cylindrical unit, and angled uniformly for an even pressure injection of fluid within the conveyance component thereof.

The invention discloses an application of a Morindae officinalis extract product and Morindae officinalis oligosaccharide 6 glycan in the preparation of medicines for resisting myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury are body injuries caused by the afresh circulation establishment and the blood supply recovery during the stopping or abnormality of the myocardial blood perfusion, like ischemic and anoxic injuries. The Morindae officinalis oligosaccharide 6 glycan has a protect effect on an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purify-cultured mouse myocardial cell reoxygenation injury model, can substantially reduces the myocardial infarction area, can mitigate the reperfusion arrhythmia, can effectively protect the form of myocardial cells, and can mitigate the injuries of anoxic reoxygenation to the myocardial cells. The therapeutic angiogenesis promotion is characterized in that the ischemic myocardial blood supply recovery and the cardiac function improvement are realized by increasing the functional coronary arterial tree or coronary collateral through some irradiations comprising the treatment effects of some medicines.

The invention discloses a medicine for treating sepsis myocardial dysfunction. The medicine consists of an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is prepared from the following raw materials: cassia twig, radix salviae miltiorrhizae, radix pseudostellariae, styrax ester, calculus bovis factitius and radix et rhizoma rhei. The traditional Chinese medicinal composition disclosed by the invention, which is prepared from the active ingredient and the excipient together, is capable of effectively improving the cardiac function of patients with sepsis myocardial dysfunction and reducing a death rate, a myocardial injury marker and an inflammatory mediator, and the traditional Chinese medicinal composition is free from an adverse reaction. The medicine fills a gap in the therapeutic field.

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and its preparing process, wherein the composition is prepared mainly from the haw thorn leaves and rhodiola root by a weight ratio of 1:0.05-10, or is prepared from haw thorn leaves flavones and rhodiola root extract by a weight ratio of 1:0.05-10. The pharmaceutical composition can be prepared into any clinically or pharmaceutically acceptable dose forms.

The invention discloses a traditional Chinese medicine composition for treating dizziness. The traditional Chinese medicine composition comprises 18 Chinese herbal medicines including radix astragali, radix ginseng, radix scutellariae, rhizoma pinellinae praeparata, radix bupleuri, rhizoma alismatis, roasted rhizoma atractylodis macrocephalae, radix glycyrrhizae preparata, radix angelicae sinensis, radix puerariae, sliced rhizoma gastrodiae, rhizoma acori graminei, rhizoma cimicifugae, rhizome ligustici wallichii, rhizoma et radix notopterygii, caulis bambusae in taeniam, radix paeoniae alba and radix curcumae. The traditional Chinese medicine composition is used for treating dizziness caused by chronic cerebral circulatory insufficiency, especially for treating and preventing qi deficiency and phlegm stagnation type dizziness caused by chronic cerebral circulatory insufficiency. In clinical tests, the traditional Chinese medicine composition is remarkable in treatment effect, the total effective rate is as high as 93.3%, and the marked effective rate is as high as 75.6%.

The liniment for treating acute and chronic soft tissue injury caused by qi stagnation and blood stasis is prepared with Chuanxiong rhizome, safflower, angelica, frankincense, myrrh and other 12 kinds of Chinese medicinal materials in certain weight proportion. The liniment has the features of easy transdermal absorption, obvious curative effect, no adverse reaction and toxic side effect and use convenience.

An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and / or vascular endothelial growth factor (VEGF). Moreover, another objective of the present invention is to provide the progenitor cells and uses thereof. In order to solve the above problems, the inventors of the present application have successfully developed a novel culture technique for producing progenitor cells from adipose tissues more efficiently compared to the conventional techniques, by using adrenomedullin (AM) and / or vascular endothelial growth factor (VEGF). The progenitor cells produced by the present inventors are specialized cells having a potent proliferation ability, a revascularization ability, and a myocardium regeneration ability, and have the property of not differentiating into adipocytes even if subjected to differentiation induction into adipocytes. Therefore, the progenitor cells of the present invention can be effective pharmaceutical agents for intractable diseases in the brain, lung, liver, kidney and the like.

The invention relates to the field of medicinal chemistry, in particular to an organic nitrite donor compound(structures shown in a general formula I and a general formula II)containing a 1nitromethyl2phenylethylene skeleton, a preparation method of the organic nitrite donor compound, and medical application of a medicinal composition of the compounds to prevention or treatment of cerebral ischemia, myocardial ischemia and pulmonary hypertension.

The invention discloses a Chinese medicine composite for treating cardiovascular diseases and a preparation method thereof. The composite is prepared from the following ingredients in portion by weight: 20.0-85.0 per cent of seabuckthorn fruit extract, 2.0-45.0 per cent of salvia miltiorrhiza extract, 1.0-40.0 per cent of ligusticum chuanxiong extract, and 5.0-50.0 per cent of borneolum syntheticum. Through pharmacodynamic experiment, the result shows that the invention has the advantages of obviously increasing coronary flow and resisting myocardial ischemia, low dose, high active ingredient, fast medicine release, high bioavailability, definite efficacy and no toxic side effect, and the like.